In ASTRIS, the biggest real-world trial of second- or later-line osimertinib in advanced or metastatic EGFR T790M NSCLC, patients were given 80 mg of osimertinib once daily if they already had undergone EGFR-TKI therapy for their malignancy [65]. Here, EGFR is linked to non-small cell lung carcinoma.